Correlation Between Oncology Pharma and Enzolytics

Can any of the company-specific risk be diversified away by investing in both Oncology Pharma and Enzolytics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncology Pharma and Enzolytics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oncology Pharma and Enzolytics, you can compare the effects of market volatilities on Oncology Pharma and Enzolytics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncology Pharma with a short position of Enzolytics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncology Pharma and Enzolytics.

Diversification Opportunities for Oncology Pharma and Enzolytics

0.16

Correlation Coefficient

Oncology Pharma  Enzolytics

Average diversification

The 3 months correlation between Oncology and Enzolytics is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding Oncology Pharma and Enzolytics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Enzolytics and Oncology Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncology Pharma are associated (or correlated) with Enzolytics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Enzolytics has no effect on the direction of Oncology Pharma i.e., Oncology Pharma and Enzolytics go up and down completely randomly.

Pair Corralation between Oncology Pharma and Enzolytics

Given the investment horizon of 90 days Oncology Pharma is expected to generate 50.69 times more return on investment than Enzolytics. However, Oncology Pharma is 50.69 times more volatile than Enzolytics. It trades about 0.35 of its potential returns per unit of risk. Enzolytics is currently generating about -0.16 per unit of risk. If you would invest  0.02  in Oncology Pharma on September 5, 2024 and sell it today you would lose (0.01) from holding Oncology Pharma or give up 50.0% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	89.06%
Values	Daily Returns

Oncology Pharma  vs.  Enzolytics

Oncology Pharma

Risk-Adjusted Performance

27 of 100

Strong

Compared to the overall equity markets, risk-adjusted returns on investments in Oncology Pharma are ranked lower than 27 (%) of all global equities and portfolios over the last 90 days. Despite fairly uncertain basic indicators, Oncology Pharma demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Enzolytics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Enzolytics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Oncology Pharma and Enzolytics

The main advantage of trading using opposite Oncology Pharma and Enzolytics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncology Pharma position performs unexpectedly, Enzolytics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enzolytics will offset losses from the drop in Enzolytics' long position.

The idea behind Oncology Pharma and Enzolytics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.